Cerebral small vessel disease(SVD)is a common global brain disease that causes cognitive impairment,ischemic or hemorrhagic stroke,problems with mobility,and neuropsychiatric symptoms.The brain damage,seen as focal wh...Cerebral small vessel disease(SVD)is a common global brain disease that causes cognitive impairment,ischemic or hemorrhagic stroke,problems with mobility,and neuropsychiatric symptoms.The brain damage,seen as focal white and deep grey matter lesions on brain magnetic resonance imaging(MRI)or computed tomography(CT),typically accumulates"covertly"and may reach an advanced state before being detected incidentally on brain scanning or causing symptoms.Patients have typically presented to different clinical services or been recruited into research focused on one clinical manifestation,perhaps explaining a lack of awareness,until recently,of the full range and complexity of SVD.In this review,we discuss the varied clinical presentations,established and emerging risk factors,relationship to SVD features on MRI or CT,and the current state of knowledge on the effectiveness of a wide range of pharmacological and lifestyle interventions.The core message is that effective assessment and clinical management of patients with SVD,as well as future advances in diagnosis,care,and treatment,will require a more"joined-up"’approach.This approach should integrate clinical expertise in stroke neurology,cognitive,and physical dysfunctions.It requires more clinical trials in order to improve pharmacological interventions,lifestyle and dietary modifications.A deeper understanding of the pathophysiology of SVD is required to steer the identification of novel interventions.An essential prerequisite to accelerating clinical trials is to improve the consistency,and standardization of clinical,cognitive and neuroimaging endpoints.展开更多
基金This work is supported by the UK Dementia Research Institute(JMW,CA)which receives its funding from DRI Ltd,funded by the UK MRC,Alzheimer's Society and Alzheimer's Research UKthe Fondation Leducq Network for the Study of Perivascular Spaces in Small Vessel Disease(JMW,16 CVD 05)+12 种基金The European Union Horizon 2020,SVDs@Target(JMW,FD,PHC-03-15,project No 666881)The Row Fogo Charitable Trust Centre for Research into Aging and the Brain(JMW)The British Heart Foundation(LACI-2 and Centre for Research Excellence,CS/15/5/31475,RE/18/5/34216)The Chief Scientist Office of Scotland(CZB/4/281,ETM/326,and Clinical Academic Fellowship UC,CAF/18/08)Chest Heart Stroke Scotland(Resl4/A157)NHS Research Scotland(FND)Stroke Association(Garfield Weston Foundation Senior Clinical Lectureship FND,TSALECT 2015/04‘Small Vessel Disease-Spotlight on Symptoms,FD,JMW,UC,SVD-SOSSAPG 19\100068R4VaD,JMW,FD,PMB,16 VAD 07Princess Margaret Research Development Fellowship,UC,2018Stroke Association Professor of Stroke Medicine PMB)PMB is a NIHR Senior Investigator.
文摘Cerebral small vessel disease(SVD)is a common global brain disease that causes cognitive impairment,ischemic or hemorrhagic stroke,problems with mobility,and neuropsychiatric symptoms.The brain damage,seen as focal white and deep grey matter lesions on brain magnetic resonance imaging(MRI)or computed tomography(CT),typically accumulates"covertly"and may reach an advanced state before being detected incidentally on brain scanning or causing symptoms.Patients have typically presented to different clinical services or been recruited into research focused on one clinical manifestation,perhaps explaining a lack of awareness,until recently,of the full range and complexity of SVD.In this review,we discuss the varied clinical presentations,established and emerging risk factors,relationship to SVD features on MRI or CT,and the current state of knowledge on the effectiveness of a wide range of pharmacological and lifestyle interventions.The core message is that effective assessment and clinical management of patients with SVD,as well as future advances in diagnosis,care,and treatment,will require a more"joined-up"’approach.This approach should integrate clinical expertise in stroke neurology,cognitive,and physical dysfunctions.It requires more clinical trials in order to improve pharmacological interventions,lifestyle and dietary modifications.A deeper understanding of the pathophysiology of SVD is required to steer the identification of novel interventions.An essential prerequisite to accelerating clinical trials is to improve the consistency,and standardization of clinical,cognitive and neuroimaging endpoints.
